CAR-T
BioNTech’s CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
Sana slashes staff and drops in vivo CAR-T program to cut costs
Sana Biotechnology, amid challenging stock performance, is undergoing its second significant restructuring in less than a year. This move involves ...
BMS invests more in Cellares to boost cell therapy manufacturing
Just six weeks following the initial announcement of a partnership between cell and gene therapy manufacturer Cellares and Bristol Myers ...
AbbVie drops Caribou’s CRISPR-edited CAR-T therapies after failed trials
AbbVie has chosen to end its partnership with Caribou Biosciences, signaling a significant shift in its strategic focus. This decision ...
Hemogenyx clears FDA hurdle for its novel CAR-T therapy for AML
Hemogenyx Pharmaceuticals has moved a step closer to advancing its CAR-T therapy, HEMO-CAR-T, into clinical trials following the FDA’s acceptance ...
Sana cuts jobs in research area, keeps mum on numbers and programs
Sana Biotechnology, a company with a focus on CAR-T therapies, has discreetly carried out another round of layoffs, declining to ...
Cellares Announces $255M Investment Round with Bristol Myers Squibb Among Key Investors
Cellares, a pioneering cell therapy manufacturer based in South San Francisco, has introduced a unique concept in the industry with ...
Astellas Buys $50M Stake in Poseida, Boosting Gene Therapy Pipeline
Source – Poseida Therapeutics Japanese pharmaceutical company Astellas is making a strategic move by investing $50 million to acquire an ...
Kite Successfully Transfers Marketing Authorization for Yescarta CAR T-cell Therapy in Japan
Source – Gilead Sciences According to Kite Pharma on June 22, 2023, the marketing authorization for Yescarta, a chimeric antigen ...
Trial of 2seventy Bio’s AML cell treatment was put on hold following a death
Source – 2seventy bio On June 14, 2023, as a result of Seattle Children’s Therapeutics pausing a clinical study of ...
